Alopecia Areata Clinical Trials
Alopecia Areata clinical trials study new biologics, small-molecule drugs, and treatment approaches for alopecia Areata and related immune or inflammatory conditions. Corterve gathers actively recruiting Alopecia Areata studies from ClinicalTrials.gov so you can browse by location and eligibility. This is general information, not medical advice — talk with your specialist before enrolling in a study.
Recruiting Alopecia Areata studies
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataNCT07772492PHASE3AbbVieSevere Alopecia AreataLos Angeles, California
- A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)NCT07533006PHASE2Eli Lilly and CompanyAlopecia AreataFremont, California
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataNCT06873945PHASE3PfizerAlopecia AreataBirmingham, Alabama
- HCW9302 (Interleukin-2 Fusion Protein) for Alopecia AreataNCT07049328PHASE1HCW BiologicsAlopecia Areata(AA)Tampa, Florida
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataNCT07733765PHASE3PfizerAlopecia AreataEncinitas, California
- Dupilumab in the Treatment of Pediatric Alopecia AreataNCT05866562PHASE2Icahn School of Medicine at Mount SinaiAlopecia AreataIrvine, California
- CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness RegistryNCT06562270CorEvitasAlopecia AreataWaltham, Massachusetts
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataNCT06012240PHASE3AbbVieAlopecia AreataBirmingham, Alabama
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia AreataNCT06826196PHASE1, PHASE2Aldena TherapeuticsAlopecia Areata (AA)Thousand Oaks, California
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeNCT07242638PHASE2Icahn School of Medicine at Mount SinaiAtopic DermatitisNew York, New York
- CorEvitas Alopecia Areata (AA) Safety and Effectiveness RegistryNCT05745389CorEvitasAlopecia AreataWaltham, Massachusetts
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataNCT05398809PHASE2National Institute of Allergy and Infectious Diseases (NIAID)Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Bethesda, Maryland
Alopecia Areata trials by state
Alopecia Areata trials by metro
Frequently asked questions
- How do I find recruiting Alopecia Areata clinical trials?
- Browse the actively recruiting Alopecia Areata studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Alopecia Areata clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Alopecia Areata clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.